Biosimilars in Developed Economies: Overview, Status, and Regulatory Considerations
- 1 February 2020
- journal article
- research article
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 110, 104525
Abstract
No abstract availableKeywords
Funding Information
- Department of Biotechnology, Ministry of Science and Technology (BT/COE/34/SP15097/2015)
This publication has 14 references indexed in Scilit:
- US FDA proposals for naming of biologicals and labelling of biosimilarsGenerics and Biosimilars Initiative Journal, 2016
- REGULATORY GUIDELINES FOR APPROVAL OF BIOSIMILARS IN INDIA, EUROPE, BRAZIL AND CHINA: A COMPREHENSIVE OVERVIEWInternational Journal of Pharmacy and Pharmaceutical Sciences, 2016
- Japanese regulation of biosimilar products: past experience and current challengesBritish Journal of Clinical Pharmacology, 2016
- Biosimilars: Rationale and current regulatory landscapeSeminars in Arthritis and Rheumatism, 2016
- Biosimilars: A consideration of the regulations in the United States and European unionRegulatory Toxicology and Pharmacology, 2016
- Korean regulations for biosimilarsGenerics and Biosimilars Initiative Journal, 2015
- Biosimilar safety factors in clinical practiceSeminars in Arthritis and Rheumatism, 2015
- Japanese regulatory authority's perspective on biosimilarsThe Lancet Oncology, 2015
- Subsequent entry biologics (biosimilars) in Canada: approaches to interchangeability and the extrapolation of indications and usesGenerics and Biosimilars Initiative Journal, 2014
- Follow-on protein products: scientific issues, developments and challengesTrends in Biotechnology, 2009